Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis

BACKGROUND: New treatment alternatives have revolutionized the management of nAMD. However, there is limited evidence on the clinical and economic burden of nAMD in commercially insured US patients. OBJECTIVES: To examine the clinical and economic burden in patients with nAMD by disease status in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Almony, Arghavan, Keyloun, Katelyn R, Shah-Manek, Bijal, Multani, Jasjit K, McGuiness, Catherine B, Chen, Chi-Chang, Campbell, Joanna H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391196/
https://www.ncbi.nlm.nih.gov/pubmed/34464210
http://dx.doi.org/10.18553/jmcp.2021.27.9.1260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391196/
https://www.ncbi.nlm.nih.gov/pubmed/34464210
http://dx.doi.org/10.18553/jmcp.2021.27.9.1260

Ejemplares similares